This article is more than 5 years old. Information may no longer be current.
Long-term data positive for IOP-lowering efficacy of iStent
Click Here to Manage Email Alerts
WASHINGTON — Patients with mild to severe open-angle glaucoma who underwent cataract surgery and received an iStent experienced a 33% reduction in medication use and a clinically significant reduction in IOP at 5 years postop, according to a speaker here.
“The IOP reduction and, to a little lesser degree, the medication reduction is sustained at 5 years postoperatively. A higher preoperative IOP is associated with a higher reduction of IOP,” John P. Berdahl, MD, said at the American Society of Cataract and Refractive Surgery annual meeting.
The retrospective case review included 440 consecutive eyes from patients with primary open-angle glaucoma with one iStent (Glaukos). Data were collected at baseline and postoperatively at 1 day, 1 week, 1 month, 3 months, 6 months and 1 year through 5 years. IOP, number of medications and visual acuity of the patient cohort were collected.
Compared with baseline, at 5 years patients experienced a statistically significant 3.18 mm Hg reduction in IOP. Medications were reduced by 33%.
“Those greater than 24 mm Hg [of IOP] had a 12 mm Hg of average IOP lowering,” Berdahl said.
The safety profile was excellent, he said, with only 2.5% of eyes requiring an additional surgery. – by Robert Linnehan
Reference:
Berdahl JP. Evaluation of trabecular micro-bypass stent glaucoma with cataract extraction in open-angle glaucoma: long term results. Presented at: American Society of Cataract and Refractive Surgery annual meeting; April 13-17, 2018; Washington.
Disclosure: Berdahl reports he is a consultant with Glaukos.